Quipt Home Medical Reports Improved Fiscal Third Quarter 2025 Results
CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. ('Quipt' or the 'Company') (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal third quarter 2025 financial results and operational highlights. These results pertain to the three and nine months ended June 30, 2025, and are reported in United States dollars.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Profound Medical Posts Wider Loss in Q2
Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
36 minutes ago
- Globe and Mail
Braze (BRZE): A Promising Player in Marketing Tech or Just Another Risky Bet?
Explore the exciting world of Braze (NASDAQ: BRZE) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 16, 2025. The video was published on Aug. 14, 2025. Should you invest $1,000 in Braze right now? Before you buy stock in Braze, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Braze wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
38 minutes ago
- Globe and Mail
Cineverse Revenue Jumps 22 Percent in Q1
Key Points Revenue rose 22% from the prior year to $11.1 million, led by streaming and digital distribution growth. Direct operating margin improved to 57%, up 6 percentage points, despite higher operating costs. Losses widened as adjusted EBITDA fell to $(2.1) million, with cash and working capital pressure emerging. These 10 stocks could mint the next wave of millionaires › Cineverse (NASDAQ:CNVS), the streaming technology and media company, reported results on August 14, 2025. The big news: revenue rose to $11.1 million, a 22% increase year over year, fueled by gains across its streaming and theatrical content divisions. Direct operating margin increased to 57%, up from 51% in the prior-year period. However, losses deepened, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) declining to $(2.1) million, versus $(1.4) million in the prior year. There were no public analyst estimates for the quarter. Overall, this period showed solid top-line growth and operational momentum, but also highlighted ongoing investment-driven losses and emerging liquidity pressures. Metric Q1 FY 2026(Quarter Ended June 30, 2025) Q1 FY 2025(Quarter Ended June 30, 2024) Y/Y Change EPS (GAAP) $(0.21) $(0.20) (5.0%) Revenue $11.1 million $9.1 million 22.0% Direct Operating Margin 57% 51% 6.0 pp Adjusted EBITDA $(2.1) million $(1.4) million (50.0%) Cash and Cash Equivalents $2.0 million Not disclosed Business Overview and Recent Focus Cineverse operates as a digital streaming and technology company. Its business centers on delivering film, television, and original content over a range of streaming channels. The company develops software for content recommendation and distribution, maintains ownership rights to a library of over 71,000 titles, and runs direct-to-consumer (DTC) streaming services. In recent quarters, Cineverse emphasized scaling its proprietary Matchpoint software platform, expanding its streaming channels, and acquiring perpetual or long-term content rights. The company's key success factors include growing viewership, monetizing content through multi-channel distribution, and deepening technology adoption among enterprise customers and industry partners. Quarter in Detail: Revenue, Strategy, and Operations Streaming and digital revenue led growth again, increasing to $9.1 million, with monthly viewership across all channels up an estimated 38%, totaling over 4 billion minutes streamed. Base distribution revenue, which includes theatrical and DVD sales, surged 192% from the prior year to $1.0 million. Management directly attributed the large increase in Q4 FY2025 to strong performance from the Terrifier 3 film release. Direct operating margin rose to 57%, up 6 percentage points from the prior-year period. That said, profitability remained under pressure. The company's net loss (GAAP) widened to $(3.6) million, or $(0.21) per share. Adjusted EBITDA, a non-GAAP measure of operating earnings before interest, taxes, depreciation, and amortization, declined to $(2.1) million, falling 50% from the previous year's level. Management pointed to 'Investments in SG&A and marketing to support our expanding theatrical business and our Technology Group' as drivers of these increased losses, while signaling expectations that returns from these investments would start to show in Q2 FY2026. Selling, general, and administrative (SG&A) expenses rose 36% to $9.0 million. The increase was attributed to ramped-up spending on compensation, legal, and marketing, as well as costs linked to year-end audit, tax, and regulatory compliance. The company signaled its strategic approach: front-load spending in content and technology to prioritize longer-term growth and market share. Notably, Cash and cash equivalents were $2.0 million. The line of credit remained largely untapped, with $8.9 million available at quarter-end and an additional $5.8 million of cash received in July 2025 from the redemption of nearly two million warrants. However, with working capital turning negative at $(0.3) million. Technology, Content, and Platform Initiatives The company's Matchpoint technology platform, which provides automated content distribution and data analytics for streaming operators, continued to be a core strategic focus. During the quarter, Cineverse launched cineSearch, an artificial intelligence (AI)-based content recommendation tool, on the Google Cloud Marketplace. It also began pilots for Matchpoint Dispatch with major studio partners during Q4 FY2025, aiming to expand from small operators to enterprise-scale adoption. A new executive was brought in to lead the technology group, signaling further intent to commercialize these assets. For content, Cineverse's business model centers on acquiring and distributing rights to genre films and family entertainment. Its strategy involves owning distribution rights for the long term, seeking to reduce risk and maximize reward if a property achieves break-out success. Management noted the upcoming releases of The Toxic Avenger Unrated, Silent Night, Deadly Night, and Return to Silent Hill across fiscal 2026. The film slate is balanced across horror and family genres. Audience growth remained a highlight. Monthly viewers rose to 209 million, a 20% increase, and total minutes streamed climbed 38%. Each segment saw gains versus the prior-year period, with Screambox -- Cineverse's horror and genre streaming channel -- reporting a 27% spike in viewership following the Terrifier 3 release. Subscription video-on-demand (SVOD) users hit 1.38 million. The company claimed a market valuation of approximately $40 million on its digital content library as of March 31, 2024, though the book value reflected on its June 30, 2025 balance sheet is just $2.9 million. Strategic partnerships also expanded this quarter. Cineverse formed MicroCo, a new joint venture targeted at microseries and short-form drama, with industry players including Banyan Media. The company also acquired U.S. rights for Air Bud Returns, developed connections with new podcast networks, and solidified technology relationships through products like cineSearch. Management Outlook and What to Watch Next Management expects returns from its investments in both film and technology to begin emerging next quarter. Technology pilots for Matchpoint and cineSearch are also entering commercial stages, with management highlighting potential annual revenue in the 'mid-7-figure' range if trials convert to enterprise deals, as discussed on the Q4 FY2025 earnings call. However, no formal revenue or profit guidance was provided for the year ahead, and management did not issue new dividend guidance or declare a dividend for common shareholders. Looking ahead, investors will be watching revenue streams from new theatrical releases. Liquidity and working capital levels also bear monitoring, given the current low cash balance and negative working capital position. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025
